Filter by
 

Type of content

Publication date

Main subject

Main subject

Keywords

Keywords

Target audience

Series/ Type

Series/type

Search tool

Displaying 121 - 134 of 134

Publications

EMCDDA–Europol 2007 Annual Report on the implementation of Council Decision 2005/387/JHA

01.05.2008

This report presents the results and outlines the key achievements and challenges faced by mechanism set up by the Council Decision in 2007. In 2007, 15 new psychoactive substances were officially notified for the first time in the European Union through the Early-Warning System (EWS). The number...

Publications

Early-warning system on new psychoactive substances — operating guidelines

01.10.2007

These practical guidelines have been published to assist the implementation of the Council decision on information exchange, risk-assessment and control of new psychoactive substances. They deal with phase 1 of the measures foreseen — the early-warning system.

Publications

EMCDDA–Europol 2006 Annual Report on the implementation of Council Decision 2005/387/JHA

01.05.2007

This report presents the results and outlines the key achievements and challenges faced by mechanism set up by the Council Decision in 2007. In 2006, 7 new psychoactive substances were officially notified for the first time in the European Union through the Early-Warning System (EWS). The number of...

Publications

Europol–EMCDDA Joint Report on a new psychoactive substance: 1-benzylpiperazine (BZP)

01.02.2007

In December 2006, after examining the available information collected on BZP (1-benzylpiperazine), the EMCDDA and Europol decided to launch a procedure for the production of a Joint Report. Pursuant to the findings of this report, the Council of the EU formally requested a risk assessment of the...

Publications

EMCDDA–Europol 2005 Annual Report on the implementation of Council Decision 2005/387/JHA

01.05.2006

The report outlines the results of the implementation of the Council Decision in 2005 and describes some issues arising from the initial experiences. In 2005, 14 new psychoactive substances were officially notified for the first time through the information exchange mechanism/EWS set up by the...

Publications

Europol–EMCDDA Joint report on a new psychoactive substance: 1-(3-chlorophenyl) piperazine (mCPP)

01.12.2005

In August 2005, after examining the available information collected on mCPP (1-(3-chlorophenyl)piperazine), the EMCDDA and Europol decided to launch a procedure for the production of a Joint report. The report concluded that mCPP seemed unlikely to establish itself as a recreational drug in its own...

Publications

Report on the risk assessment of TMA-2 in the framework of the joint action on new synthetic drugs

01.05.2004

The risk-assessment report on the synthetic drug TMA-2 was submitted by the EMCDDA to the European Council and Commission on 4 April 2003. The report was drawn up at a meeting in Lisbon from 31 March to 1 April under the auspices of an enlarged EMCDDA Scientific Committee. The drug was singled out...

Publications

Report on the risk assessment of 2C-I, 2C-T-2 and 2C-T-7 in the framework of the joint action on new synthetic drugs

01.05.2004

The risk-assessment reports on the synthetic drugs 2C-I; 2C-T-2 and 2C-T-7 were submitted by the EMCDDA to the European Council and Commission on 4 April 2003. The reports were drawn up at a meeting in Lisbon from 31 March to 1 April under the auspices of an enlarged EMCDDA Scientific Committee....

Publications

Report on the risk assessment of PMMA in the framework of the joint action on new synthetic drugs

01.03.2003

The report assesses the risks of PMMA, especially in association with the already controlled substance PMA (para-methoxyamphetamine). PMMA, is an amphetamine-like substance very close to PMA, and is almost exclusively sold in tablet form in combination with the latter and consumed as ‘ecstasy’. It...

Publications

Report on the risk assessment of ketamine in the framework of the joint action on new synthetic drugs

01.06.2002

Since the mid-1990s, ketamine – widely used in human and veterinary medicine for 30 years – has been surfacing as a recreational drug. Concern over ketamine centres on its unpredictability in producing ‘near-death’ experiences. The risk-assessment exercise was carried out in 2000 in the framework...

Publications

Report on the risk assessment of GHB in the framework of the joint action on new synthetic drugs

01.06.2002

Since the mid-1990s, GHB – widely used in human and veterinary medicine for 30 years – has been surfacing as a recreational drug. Some EU countries have reported worries over GHB’s surreptitious use in sexual assaults. Although the extent of this is unknown, the EMCDDA and its risk-assessment...

Publications

Report on the risk assessment of 4-MTA in the framework of the joint action on new synthetic drugs

01.10.1999

An enlarged EMCDDA Scientific Committee met from 18–19 May 1999 in Lisbon to assess the risks of the synthetic drug 4-MTA (4-methylthioamphetamine) in the framework of the Joint action on new synthetic drugs. The Committee's tasks were to assess the health and social risks of the substance and the...

Publications

Guidelines for the risk assessment of new synthetic drugs

01.08.1999

This publication was drawn up by the steering group created by the EMCDDA's Scientific Committee in November 1998 to establish guidelines to assess the risks of all new synthetic drugs identified under the terms of the Joint Action concerning the information exchange, risk assessment and control of...

Publications

Report on the risk assessment of MBDB in the framework of the joint action on new synthetic drugs

01.06.1999

On 27 February 1998, the drug MBDB (N-methyl-1-(1,3-benzodioxol- 5-yl)-2-butanamine) became the first new synthetic drug to be submitted for risk assessment under the terms of the Joint Action concerning the information exchange, risk assessment and control of new synthetic drugs adopted on 16 June...
Loading